1. Zhan, T., Xiong, H., Pang, J., Zhang, W., Ye, Y., Liang, Z., Huang, X., He, F., Jian, B., He, W., Gao, Y., Min, X., Zheng, Y., & Yang, H. (2021). Modulation of NAD+ biosynthesis activates SIRT1 and resists cisplatin-induced ototoxicity. Toxicology letters, 349, 115–123. https://doi.org/10.1016/j.toxlet.2021.05.013
2. Paken, J., Govender, C. D., Pillay, M., & Sewram, V. (2016). Cisplatin-Associated Ototoxicity: A Review for the Health Professional. Journal of toxicology, 2016, 1809394. https://doi.org/10.1155/2016/1809394
3. Brown, K. D., Maqsood, S., Huang, J. Y., Pan, Y., Harkcom, W., Li, W., Sauve, A., Verdin, E., & Jaffrey, S. R. (2014). Activation of SIRT3 by the NAD⁺ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell metabolism, 20(6), 1059–1068. https://doi.org/10.1016/j.cmet.2014.11.003
https://doi.org/10.1016/j.cmet.2014.11.003
4. Yoo, K. H., Tang, J. J., Rashid, M. A., Cho, C. H., Corujo-Ramirez, A., Choi, J., Bae, M. G., Brogren, D., Hawse, J. R., Hou, X., Weroha, S. J., Oliveros, A., Kirkeby, L. A., Baur, J. A., & Jang, M. H. (2021). Nicotinamide Mononucleotide Prevents Cisplatin-Induced Cognitive Impairments. Cancer research, 81(13), 3727–3737. https://doi.org/10.1158/0008-5472.CAN-20-3290